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Abstract: Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies 
with a typical onset early in the life. Infants with these disorders have frequently chronic 
diarrhea of sufficient severity to require parenteral nutrition. For most CDDs the  
disease-gene is known and molecular analysis may contribute to an unequivocal diagnosis. 
We review CDDs on the basis of the genetic defect, focusing on the significant contribution 
of molecular analysis in the complex, multistep diagnostic work-up. 
Keywords: molecular analysis; osmotic diarrhea; secretory diarrhea; defects of digestion; 
absorption and transport of nutrients and electrolytes; defects of enterocyte differentiation  
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and polarization; defects of enteroendocrine cells differentiation; defects of modulation of 
intestinal immune response 
 
Abbreviations: ADE: acrodermatitis enteropathica; AIRE: autoimmune regulator;  
ALP: abetalipoprotenemia; APL: absence of pancreatic lipase; APS1: autoimmune polyglandular 
syndrome type 1; CCD: congenital chloride diarrhea; CDD: congenital diarrheal disorders; CF: cystic 
fibrosis; CFTR: cystic fibrosis transmembrane regulator; CMD: congenital malabsorptive diarrhea; 
CRD: chilomicron retention disease; CSD: congenital sodium diarrhea; CTE: congenital tufting 
enteropathy; EpCAM: epithelial cellular adhesion molecule; EKD: enterokinase deficiency;  
FBS: Fanconi-Bickel syndrome; FM: fructose malabsorption; GGM: glucose-galactose malabsorption; 
GLUT: glucose transporter; HLP: hypobetalipoproteinemia; HP: hereditary pancreatitis; IPEX: immune 
dysfunction, polyendocrinopathy, X-linked; LD: lactase deficiency; LPI: lysinuric protein intolerance; 
MTTP: microsomal triglyceride transfer protein; MVID: microvillous inclusion disease;  
MGD: maltase-glucoamylase deficiency; MGAM: maltase-glucoamylase (gene and protein);  
NHE: sodium-proton exchanger; PBAM: primary bile acid malabsorption; PCD: proprotein convertase 
1/3 deficiency; SDS: Shwachman-Diamond syndrome; SID: sucrase-isomaltase deficiency;  
SLC: solute carrier; SNP: single nucleotide polymorphism; SPINT: serine protease inhibitor;  
THE: Tricho-Hepato-Enteric syndrome 
List of Gene Designations: AIRE; CFTR; EpCAM; FOXP3; Interleukin-2 receptor (subunit CD25); 
MGAM; MTTP; MYO5B; NEUROG3; NHE; PCD; SBDS; SLC2A2; SLC5A1; SLC7A7; SLC10A2; 
SLC26A3; SLC39A4; SPINT2 
1. Introduction 
Congenital diarrheal disorders (CDDs) are a group of inherited enteropathies with a typical onset 
early in the life [1–3]. Most CDDs display similar clinical presentation despite different outcomes.  
For many of these conditions, severe chronic diarrhea represents the main clinical manifestation, while 
in others, diarrhea is only a component of a more complex multiorgan or systemic disease. In the vast 
majority of cases appropriate therapy must be started immediately to prevent dehydration and long 
term, and sometimes life-threatening, complications [2]. Milder forms of CDDs, with less severe 
clinical picture that remain undiagnosed until later ages, have been described. The less severe outcome 
may depend on a milder effect of mutations in the disease gene [1–3]. In most cases of CDDs the 
disease-gene is known [4]. Thus, molecular analysis has become a major advantage in the difficult 
diagnostic approach to a patient with suspected CDDs [5]. We recently proposed a CDDs classification 
in four groups: (i) defects of digestion, absorption and transport of nutrients and electrolytes;  
(ii) defects of enterocyte differentiation and polarization; (iii) defects of enteroendocrine cell 
differentiation; (iv) defects of modulation of intestinal immune response [3]. This classification could 
be adopted as practical starting point for the complex diagnostic approach to patients with CDDs. This 
article is mainly focused on the updated diagnostic work up for these conditions pointing out the 
contribution of molecular analysis. 
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2. The Contribution of Epidemiological Data to the Diagnostic Approach  
The exact incidence of most CDDs remains to be established, but in some cases data are available 
(Tables 1–4). The knowledge of the incidence of CDDs in specific countries and ethnic groups could 
help the physician. Some CDDs are more frequent in ethnic groups where consanguineous marriages 
are usual, or in some geographic areas due to founder effect [1–3,6]. For example, congenital lactase 
deficiency (LD) is particularly frequent in Finland [3,4]; lysinuric protein intolerance (LPI) has a higher 
incidence either in Finland and in Japan due to founder effect, and a single mutation is typically found 
in each of the two ethnic groups; also in southern Italy there are several affected patients [7]; congenital 
sucrose-isomaltase deficiency (SID) may affect up to 5% of the populations in Greenland, Alaska and 
Canada [8]. Similarly, congenital chloride diarrhea (CCD) is sporadic worldwide and a large genetic 
heterogeneity has been reported in about 150 patients described so far [9–11], while in some ethnics 
CCD has a higher frequency due to founder effect in Finland, Saudi Arabia, Kuwait and Poland. 
Table 1. Inheritance, epidemiology and main pathological mechanisms of the defects of 
digestion, absorption and transport of nutrients and electrolytes. 
Disease 
OMIM 
number 
Transmission and incidence Mechanism 
Genes encoding brush-border enzymes 
Congenital lactase deficiency (LD) 223000 
AR, 1:60.000 in Finland; lower in 
other ethnic groups 
Osmotic 
Congenital sucrase-isomaltase deficiency (SID) 222900 
AR, 1:5.000; higher incidence in 
Greenland, Alaska and Canada 
Osmotic 
Congenital maltase-glucomaylase deficiency 
(MGD) 
-- Few cases described Osmotic 
Enterokinase deficiency (EKD) 226200 AR Osmotic 
Genes encoding membrane carriers 
Glucose-galactose malabsorption (GGM) 606824 AR, few hundred cases described Osmotic 
Fructose malabsorption (FM) 138230 - Osmotic 
Fanconi-Bickel syndrome (FBS) 227810 AR Osmotic 
Acrodermatitis enteropathica (ADE) 201100 AR, 1:500.000 Osmotic 
Congenital chloride diarrhea (CCD, DIAR 1) 214700 
AR, sporadic; frequent in some 
ethnies 
Osmotic 
Congenital sodium diarrhea (CSD, DIAR 3) 270420 AR Osmotic 
Lysinuric protein intolerance (LPI) 222700 
AR, about 1:60.000 in Finland and in 
Japan; rare in other ethnic groups 
Osmotic 
Primary bile acid malabsorption (PBAM) 613291 AR Secretory 
Cystic fibrosis (CF) 219700 AR, 1:2.500 Osmotic 
Genes encoding pancreatic enzymes and pancreatic ions transporters 
Hereditary pancreatitis (HP) 167800 AD Osmotic 
Congenital absence of pancreatic lipase (APL) 246600 -- Osmotic 
Genes encoding proteins of lipoprotein metabolism 
Abetalipoproteinemia (ALP) 200100 
AR, about 100 cases described; 
higher frequency among Ashkenazi 
Osmotic 
Hypobetalipoproteinemia (HLP) 107730 Autosomal co-dominant Osmotic 
Chilomicron retention disease (CRD) 246700 AR, about 40 cases described Osmotic 
Genes encoding ribosomial proteins 
Shwachman-Diamond syndrome (SDS) 260400 AR 1:10–200.000 Osmotic 
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Table 2. Inheritance, epidemiology and main pathological mechanisms of the defects of 
enterocyte differentiation and polarization. 
Disease 
OMIM 
number 
Transmission and incidence Mechanism 
Microvillous inclusion disease (MVID, DIAR 2) 251850 
AR; rare; higher frequency among 
Navajo 
Secretory 
Congenital tufting enteropathy (CTE, DIAR 5) 613217 
AR; 1:50–100.000; higher frequency 
among Arabians 
Secretory 
Tricho-Hepato-Enteric syndrome (THE) 222470 AR, 1:400.000 Secretory 
Table 3. Inheritance, epidemiology and pathological mechanisms of the defects of 
enteroendocrine cells differentiation. 
Disease OMIM number Transmission and incidence Mechanism 
Congenital malabsorptive diarrhea 
(CMD, DIAR 4) 
610370 AR; few cases described Osmotic 
Proprotein convertase 1/3 deficiency 
(PCD) 
600955 AR Osmotic 
Table 4. Inheritance, epidemiology and main pathological mechanisms of the defects of 
modulation of intestinal immune response. 
Disease 
OMIM 
number 
Transmission and incidence Mechanism 
Autoimmune polyglandular syndrome type 1 
(APS1) 
240300 AR; AD (1 family) Secretory 
Immune dysfunction, polyendocrinopathy,  
X-linked (IPEX) 
601410 
X linked (autosomal cases described), 
very rare 
Secretory 
IPEX-like syndrome -- not X-linked Secretory 
3. The Initial Steps of Diagnostic Work Up 
The diagnostic approach to CDDs is a multistep process that includes the careful evaluation of the 
anamnesis and clinical data, results of common laboratory and instrumental procedures and molecular 
analysis (Figures 1–3). Positive familiar history of early onset chronic diarrhea, polyhydramnios and/or 
dilated bowel loops at ultrasound examination during pregnancy are highly suggestive of CDDs. 
Frequently CDDs dates to early neonatal period [2,3]. However in the approach to a newborn or infant 
with suspected CDDs it is important to remember that also at this particular age, infections and food 
allergy are frequent causes of chronic diarrhea [6], and that these conditions together with malformations 
of gastrointestinal tract should be considered as primary hypothesis [2,3]. 
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Figure 1. Identification of pathogenetic osmotic or secretory mechanisms leading to diarrhea. 
 
  
Diarrhea ceases with fasting
and/or
ion gap > 50
Osmotic
Diarrhea persist with fasting
and/or
ion gap < 50 
Secretory
Evaluate
1) Diarrhea relation with fasting
2) Fecal ion concentrations and ion gap1
Main step in the diagnosis
Results of diagnostic procedures
Pathogenetic mechanism
Figure 1. Identification of pathogenetic osmotic or secretory mechanisms leading to diarrhea.
Note. (1) Ion gap =  290 – 2 [Na+] + [K+] 
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Figure 2. Panel A. Diagnostic diagram of congenital diarrheal disorders determined by an osmotic mechanism. Panel B. Diagnostic diagram 
of congenital diarrheal disorders determined by an osmotic mechanism. 
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Figure 2. Panel B. Diagnostic diagram of congenital diarrheal disorders determined by an osmotic mechanism.
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Figure 3. Diagnostic diagram of congenital diarrheal disorders determined by a secretory mechanism. 
 
Figure 3. Diagnostic diagram of congenital diarrheal disorders determined by a secretory mechanism.
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dimorphisms (facial 
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No inflammation
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abdominal pain
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Note. (1) Molecular analysis may precede biopsy.    
Molecular analysis 
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Once suspected, the fundamental step in the diagnostic process of CDDs is the identification of an 
osmotic or secretory mechanism leading to diarrhea (Figure 1). In osmotic diarrhea unabsorbed 
luminal substances are responsible for accumulation of fluids in intestinal lumen and diarrhea 
significantly improves during fasting, whereas in secretory diarrhea fluids are actively secreted in the 
intestinal lumen and diarrhea continues during fasting [12]. Furthermore, the determination of stool 
electrolyte concentration and fecal ion gap are important to discriminate the two mechanisms 
responsible of CDDs (Figure 1). 
If ion gap is >50 fecal osmolarity derived from ingested osmotically active nutrient or non 
measured ion (i.e., Cl
−
, Mg
2+
). In contrast a low osmotic gap (<50) is typically observed in secretory 
diarrhea. It is also important to measure Cl
−
 concentration in the stool to rule out CCD, characterized 
by low ion gap due to high Cl
−
 fecal loss (>90 mmol/L) [13]. When an osmotic mechanism is 
suspected the next step of laboratory investigation includes blood gas, blood glucose, ammonium, 
albumin, triglycerides and cholesterol, aminoaciduria and the search of reducing substances in the 
stools, steatocrit and sweat test (Figure 2). Finally, intestinal biopsy with hystologic examination is 
crucial for the diagnosis of most CDDs, more frequently for secretory forms; even if molecular 
analysis, when available, could limit invasive procedures (Figures 2 and 3). 
3.1. Congenital Osmotic Diarrheal Disorders 
The main conditions included in this subgroup are characterized by carbohydrate malabsorption 
with subsequent bacteria fermentation and increased lactic acid concentration in stools [14]. The 
detection of fecal reducing substances by Clinitest (normal value < 0.5%) may suggest carbohydrate 
malabsorption. A stool pH between 5 and 6 is indicative but, finally, unreliable screening test for the 
diagnosis of sugar malabsorption. Breath test and diet trials are used to address clinical suspect. Small 
bowel disaccharidase activity measurement on intestinal biopsy could be avoided especially when 
molecular analysis is available (Figure 2). In the absence of carbohydrate malabsorption in a patient 
with osmotic diarrhea, it is essential to determine if steatorrhea is present. Although diarrhea alone 
may be responsible for an increase fat excretion, and generalized malabsorptive diseases may induce 
steatorrhea, greater rates of fat malabsorption can be explained only by one or more defects in fat 
digestion and absorption [2,3]. Fat malabsorption can be divided into three broad categories: 
intraluminal maldigestion (pancreatic insufficiency), mucosal malabsorption, and post-mucosal 
malabsorption related to lymphatic obstruction [15,16]. 
Low triglycerides and cholesterol serum levels are typically observed in children with a- or  
hypo-betalipoproteinemia (ALP/HLP). Biopsy is useful to confirm diagnosis of ALP/HLP. However, 
molecular diagnosis may be used at this point of diagnostic work up to avoid invasive procedures. Bile 
salts are particularly important in lipids digestion and absorption. However, in primary bile acid 
malabsorption (PBAM) diarrhea is generally secretory in nature (persist while fasting) and is 
exacerbated by the addition of dietary fats (see also Figure 3). Among osmothic CDDs, the onset of 
symptoms after ingestion of specific food or the presence of extraintestinal symptoms could help the 
diagnosis. Fructose malabsorption should be suspected when consumption of fruit juices that contain a 
high proportion of fructose to glucose or an excessive amount of the non-absorbable carbohydrate 
sorbitol are associated with diarrhea and abdominal pain [17]. Disorders of protein digestion are 
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unusual but should be considered when evaluating a patient with suspected CDDs. The best 
characterized disorder of specific protein malabsorption is the enterokinase deficiency (EKD) [18]. 
Individuals with EKD present diarrhea and hypoproteinemic edema when on diet with intact proteins, 
while symptoms resolve on an amino acids-based diet. The presence of diarrhea associated with 
tubular nephropathy, hepatomegaly and abnormal glycogen accumulation, and fasting hypoglycemia 
suggest the presence of Fanconi-Bickel Syndrome (FBS) [19]. The vesciculus bullous dermatitis, 
located on the hands, feet, perirectal and oral region, and alopecia are a consequence of Zn
2+
deficiency 
that could be due to excessive fecal losses of Zn
2+
 observed in acrodermatitis enteropathica (ADE) [20]. 
Severe Zn
2+
 deficiency can present also with anorexia, failure to thrive, immunodeficiency and 
neurologic features (mental lethargy and neurosensory abnormalities) associated with chronic diarrhea. 
A particular form of osmotic diarrhea genetically determined is the enteric anendocrinosis (or 
congenital malabsorptive diarrhea, CMD) [21]. The salient pathological fact is that the mucosa of the 
small intestine is essentially normal, except for the absence of enteroendocrine cells and of the enteric 
hormones. The number of patients described so far is too small to draw reliable conclusions about the 
typical clinical picture of CMD. However, the diarrhea in this condition is undoubtedly of osmotic 
nature. While water is well tolerated, glucose-based oral rehydration solution leads to diarrhea and the 
patients continue to experience diarrhea while on carbohydrate-free cow’s milk or amino-acids based 
formulas. These infants may be optimally managed with life-long parenteral nutrition and limited 
enteral nutrition [21]. 
3.2. Congenital Secretory Diarrheal Disorders 
In the approach to the infant presenting with early onset secretive chronic diarrhea intestinal biopsy 
is generally considered useful to identify the major forms of CDDs included in this subgroup  
(i.e., enterocytes differentiation and polarization and modulation of intestinal immune response), but 
also in these cases molecular diagnosis may help to limit invasive approaches (Figure 3). When villous 
atrophy is not accompanied by an inflammatory infiltrate, defect of enterocyte differentiation and 
polarization including microvillous inclusion disease (MVID) and congenital tufting enteropathy (CTE) 
are plausible [22]. For MVID and CTE, pregnancy and delivery are uneventful, and polyhydramnios is 
unusual. In these conditions severe diarrhea occurs within the first weeks of life and rapidly requires 
total parenteral nutrition. Several cases of CTE have been reported as being associated with phenotypic 
abnormalities including dysmorphic facial features, choanal atresia, esophageal atresia, and keratitis. 
Molecular diagnosis may be an option to avoid radiological exposure [2,3]. Immune dysfunction, 
polyendocrinopathy X-linked syndrome (IPEX) appears as a secretory diarrhea of inflammatory nature 
associated with dermatitis, diabetes mellitus, thyroiditis, and hematologic disorders [23–25]. Most 
patients develop a protein-loosing enteropathy with α-1-antitrypsin loss in stools, and 
hypoalbuminemia [2]. Diarrhea often starts within 3 months of life; however a later onset has 
occasionally been described [3]. 
4. Genetic Basis of CDDs 
Most CDDs are transmitted as an autosomal recessive trait even if with some exceptions. Below, 
we report the main genetic characteristics of the 4 groups of CDDs.  
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4.1. Defects of Digestion, Absorption and Transport of Nutrients and Electrolytes 
This group can be further divided in various subgroups on the basis of the specific gene defect.  
The first subgroup includes the deficiency of brush border enzymes, and in particular congenital LD 
due to mutations within the gene encoding the protein with either lactase and phlorizin hydrolase 
activities [26]; congenital SID, due to mutations in the gene encoding the protein with both sucrase and 
isomaltase activity [8], and congenital maltase-glucoamylase deficiency (MGD), putatively due to the 
maltase-glucoamylase (MGAM) gene defect [8], even if some patients with the disease do not bear 
pathogenetic mutations in such gene. In fact, cases in which MGD was associated to the deficiency of 
other brush border enzymes were described, and it has been postulated that a pleiotropic regulator 
factor of such genes may be impaired in these patients [27]. 
A large subgroup derives from mutations of genes encoding members of the super-family of solute 
carriers (SLC). These genes are structurally related and originated by mechanisms of duplication, but 
despite the homology of the gene sequence and the similarity of the protein architecture, the clinical 
picture and the outcome of these CDDs is heterogeneous. Most proteins encoded by SLC genes  
are expressed at intestinal level, thus the disease typically appears with diarrhea and selective 
malabsorption. In other cases the carrier is expressed also in other organs (i.e., the aminoacid 
transporter involved in LPI is expressed also in other tissues) and thus the disease could involves other 
organs or be systemic [7]. For some CDDs disease-genes are still unknown or more genes may be 
involved. For example, the disease gene for fructose malabsorption is still undefined [8,17,28]. There 
remains insufficient evidence that glucose transporter (GLUT) 5 represents the main fructose 
facilitative carrier in the intestine [17,28]. Recent studies have identified GLUT7 as a high affinity 
glucose and fructose carrier on the brush border membrane of the enterocyte located in the distal 
intestine. Other studies suggest also a role of GLUT2 in the absorption of large amount of fructose 
across the enterocyte of the rats. In particular, the disease-gene for congenital sodium diarrhea (CSD) 
is unknown [3], and a study based on the candidate gene approach failed to identify the responsible 
among the 6 known isoforms of sodium-proton exchangers (NHE) 1 to 6. However, in addition to 
classic CSD characterized by perinatal onset of severe diarrhea there is a syndromic form of the 
disease. The disease gene of the syndromic CSD is serine protease inhibitor (SPINT) 2 [29], which 
encodes a serine-protease inhibitor, recently identified using genome-wide single nucleotide 
polymorphism (SNP) linkage analysis in a large family. Mutations of the gene were identified in all 
other four syndromic patients studied. On the contrary, no mutations were identified in patients bearing 
the classic form of the disease [29,30]. A third subgroup involves genes encoding specific enzymes 
like the congenital absence of pancreatic lipase (APL) [31], that is a rare disease associated to 
malabsorption, steatorrhea and severe diarrhea. Also included in this group are hereditary pancreatitis 
(HP) [32]. However, it could be important to underline that some cases of chronic hereditary 
pancreatitis derive from mutations in the cystic fibrosis transmembrane regulator (CFTR) gene [33].  
A fourth subgroup of rare and congenital disorders of lipoprotein metabolism can appear with 
chronic diarrhea. Familial ALP is due to mutations in microsomal triglyceride transfer protein (MTTP) 
gene which encodes the MTT protein involved in the synthesis of beta lipoproteins [34,35]. Familial 
HLP is a relatively mild disease that may appear with chronic diarrhea and fatty liver [36]. It depends 
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on co-dominant mutations in the ApoB gene, but in some cases a linkage to chromosome 3 (3p21) was 
found [37].  
The last subgroup includes CDDs deriving from mutations of genes encoding ribosomial proteins. 
The SDS is a systemic disease due to mutations in the SBDS gene that encodes a protein whose 
function is still largely obscure [38,39]. Most of these mutations cause exchange of genetic material 
(gene conversion) between SBDS and a close pseudogene.  
4.2. Defect of Enterocyte Differentiation and Polarization 
CDDs due to defects of enterocyte differentiation and polarization include three rare and severe 
forms. Congenital microvillous inclusion disease (MVID, DIAR2) is one of the most frequent cause of 
CDDs in neonates [40]. The disease is due to a loss of function of Myosin5B, a protein involved in the 
recycling of endosomes, encoded by the MYO5B gene. Molecular analysis can be performed, thus 
reducing the need of invasive approaches and electronic microscopy [4,40], but some MVID patients 
have been described with one or none mutations in such gene [4,40]. Congenital tufting enteropathy is 
a rare, early onset (first days after birth), diarrheal disease [41], due to mutations in the gene encoding 
the epithelial cellular adhesion molecule (EpCAM). The reduced activity of such protein causes the 
lack of lateral interactions and desmosomal alterations typical of CTE. Also in such disease, the 
availability of molecular analysis reduced the need of invasive approaches and of electronic microscopy. 
Finally, the Tricho-Hepato-Enteric (THE) syndrome, is a rare and poorly tractable chronic diarrhea 
associated to facial dysmorphism and immunological alterations [42]. In addition to this, for such 
diseases, molecular analysis will help to obtain unambiguous and rapid diagnosis, thus reducing the 
need for invasive approaches (Figure 2).  
4.3. Defects of Enteroendocrine Cells Differentiation 
This group includes CMD (DIAR4) and proprotein convertase 1/3 deficiency (PCD). The CMD is 
very uncommon [43]; it appears with a very severe diarrhea since the first days of life and is 
characterized by the dysgenesis of enteroendocrine cells (the first name of the disease was enteric 
anendocrinosis). In some CMD patients molecular analysis revealed mutations in the NEUROG 3 gene 
that encodes neurogenin 3, a transcriptional factor strongly expressed in endocrine cells and necessary 
for the development of such cells at intestinal and pancreatic level. CMD patients may develop early 
onset diabetes [44,45]. Going to PCD, the few cases reported so far had a different age at onset and 
severity of the disease, which usually appears with small intestine dysfunction and a variable 
polyendocrinopathy. The disease is due to mutations in the proprotein convertase 1/3 (PCD) gene that 
encodes a hormone processing enzyme [46].  
4.4. Defects of Modulation of Intestinal Immune Response 
Defects of the modulation of the intestinal immune response includes some well codified entities 
like IPEX and APS1, and the not well defined IPEX-like syndrome. The IPEX syndrome, a rare  
X-linked disease, bears to the group of autoimmune polyglandular syndromes and is also known with a 
long series of acronyms [47,48]. The disease gene (i.e., FOXP3) encodes a protein involved in 
Int. J. Mol. Sci. 2012, 13 4180 
 
 
embryonic development. Molecular analysis contributes to diagnosis, and has been used also for 
prenatal diagnosis [49], but about one third of symptomatic patients are negative to molecular analysis 
(they are now indicated as IPEX-like syndrome, see below). APS1 is another of the three codified 
autoimmune polyglandular syndromes with an autosomal recessive inheritance (even if a family with a 
dominant transmission was described) [47]. APS1 may be easily diagnosed searching for mutations in 
the autoimmune regulator (AIRE) gene encoding an autoimmune regulator (AIRE) protein [50,51].  
To be noted that quite all affected patients have anti-interferon antibodies in serum. Finally, the  
IPEX-like syndrome (not X-linked despite the name) is a not well-defined disease, which includes 
patients with IPEX symptoms with no mutations in FOXP3 gene. In one of these patients a deficiency 
of CD25 due to a recessive mutation in the interleukin-2 (IL-2) receptor subunit CD25 was found [52]. 
5. Molecular Diagnosis 
In the majority of cases genes responsible for CDDs are not particularly large. This permit to use 
scanning techniques like the gene sequencing for molecular analysis, in order to reduce diagnostic 
errors. Furthermore, some CDDs in specific ethnic groups are caused by a single mutation due to the 
founder effect, while the same diseases in other ethnic groups may be due to myriad of different 
mutations. Among all the diseases listed in the Tables 1–4 only in a few cases molecular diagnosis 
cannot be routinely performed. They include: (i) congenital MGD, because no mutations have been 
identified so far in the putative disease gene MGAM in affected patients, suggesting that the disease 
may depend on other regulatory genes [27]; (ii) FM, in which more genes encoding fructose carriers may 
be involved [17]; (iii) CSD, in which only syndromic forms have mutations in the SPINT2 gene [38]; 
(iv) IPEX-like syndrome, for which the disease gene is still unknown even if a single patient had a 
mutation in the CD25 encoding gene [52]. In some CDDs like GGM, IPEX, CF [49,53] molecular 
analysis has been used for prenatal diagnosis. Given the severe outcome of most CDDs, and the 
availability of efficient techniques for gene scanning analysis, the request for prenatal diagnosis will 
increase in the next future. It is important that prenatal diagnosis would be associated to a careful 
multidisciplinary counseling to the families [54]. 
6. Conclusions 
During the last decade we have observed an impressive improvement in the field of CDDs, in terms 
of pathogenesis knowledge and in the field of diagnostic approaches. Molecular analysis has changed 
the diagnostic scenario in CDDs, and lead to reduction of invasive and expensive procedures  
(Figures 2 and 3). However, some critical points warrant a comment: (i) molecular analysis would be 
based on scanning procedures [55], including the search for large gene deletions [56], using adequate 
quality control programs [57] and well trained technologists; (ii) the laboratory must be able to perform 
functional analysis of novel mutations to demonstrate their pathogenic role; (iii) the negative result of 
molecular analysis does not exclude the disease, because mutations may involve non-coding, regulatory 
areas; high throughput sequencing could help to perform extensive analyses [55]; however, also if the 
mutation is not known, carrier and prenatal diagnosis may be performed using linkage analysis [58]; 
(iv) some CDDs are very rare; it is necessary that laboratories offer molecular diagnosis also for such 
“orphan” diseases. All these considerations permit to conclude that a few number of reference 
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laboratories involved in molecular diagnostics for CDDs should be organized in international networks. 
However, given the number of CDDs, the complexity of genotype-phenotype correlations and the need 
of multidisciplinary counseling to the families, a strict collaboration between physicians and molecular 
laboratories is mandatory in this field. 
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